EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment

Jorma Isola iD, Markku Mäki, Martin Hils iD, Ralf Pasternack, Keijo Viiri iD, Valeriia Dotsenko, Toni Montonen, Timo Zimmermann, Ralf Mohrbacher, Roland Greinwald, Detlef Schuppan

International Journal of Molecular Sciences · 2023

DOI: 10.3390/ijms241310815 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Jorma Isola und 10 weiteren Autor:innen. Beteiligte Einrichtung: Jilab Inc., 33520 Tampere, Finland. Hauptthemen laut MEDLINE: Glutens, Celiac Disease. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 16 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital, Dr. Falk Pharma.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The enzyme transglutaminase 2 (TG2) plays a key role in celiac disease (CeD) pathogenesis. Active TG2 is located mainly extracellularly in the lamina propria but also in the villous enterocytes of the duodenum. The TG2 inhibitor ZED1227 is a promising drug candidate for treating CeD and is designed to block the TG2-catalyzed deamidation and crosslinking of gliadin peptides. Our aim was to study the accumulation of ZED1227 after oral administration of the drug. We studied duodenal biopsies derived from a phase 2a clinical drug trial using an antibody that detects ZED1227 when bound to the catalytic center of TG2. Human epithelial organoids were studied in vitro for the effect of ZED1227 on the activity of TG2 using the 5-biotin-pentylamine assay. The ZED1227-TG2 complex was found mainly in the villous enterocytes in post-treatment biopsies. The signal of ZED1227-TG2 was strongest in the luminal epithelial brush border, while the intensity of the signal in the lamina propria was only ~20% of that in the villous enterocytes. No signal specific to ZED1227 could be detected in pretreatment biopsies or in biopsies from patients randomized to the placebo treatment arm. ZED1227-TG2 staining co-localized with total TG2 and native and deamidated gliadin peptides on the enterocyte luminal surface. Inhibition of TG2 activity by ZED1227 was demonstrated in epithelial organoids. Our findings suggest that active TG2 is present at the luminal side of the villous epithelium and that inhibition of TG2 activity by ZED1227 occurs already there before gliadin peptides enter the lamina propria.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlutensCeliac DiseaseHumansProtein Glutamine gamma Glutamyltransferase 2EnterocytesGliadinTransglutaminasesPeptidesImidazolesPyridines

Stichwörter der Autor:innen

brush borderceliac disease therapyenterocytegliadingluten

Substanzen

GlutensProtein Glutamine gamma Glutamyltransferase 2GliadinTransglutaminasesPeptidesZED1227ImidazolesPyridines

Autor:innen und Institutionen

  • Jilab Inc., 33520 Tampere, Finland.
  • Faculty of Medicine and Health Technology, Tampere University, 33014 Tampere, Finland.
  • Zedira GmbH, Roesslerstrasse 83, 64293 Darmstadt, Germany.
  • Dr. Falk Pharma Gmbh, 79108 Freiburg, Germany.
  • Institute of Translational Immunology and Celiac Center, Medical Center, Johannes-Gutenberg University, 55099 Mainz, Germany.
  • Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02115, USA.

ORCID-Profile: Jorma Isola, Martin Hils, Keijo Viiri

Förderung

  • The Competitive State Research Financing of the Expert Responsibility Area of Tampere University Hospital
  • Dr. Falk Pharma

Zitieren

APA

Isola, J., Mäki, M., Hils, M., Pasternack, R., Viiri, K., Dotsenko, V., Montonen, T., Zimmermann, T., Mohrbacher, R., Greinwald, R., & Schuppan, D. (2023). The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241310815

Vancouver

Isola J, Mäki M, Hils M, Pasternack R, Viiri K, Dotsenko V, et al. The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241310815

BibTeX
@article{Isola2023,
  author = {Isola, Jorma and Mäki, Markku and Hils, Martin and Pasternack, Ralf and Viiri, Keijo and Dotsenko, Valeriia and Montonen, Toni and Zimmermann, Timo and Mohrbacher, Ralf and Greinwald, Roland and Schuppan, Detlef},
  title = {The Oral Transglutaminase 2 Inhibitor ZED1227 Accumulates in the Villous Enterocytes in Celiac Disease Patients during Gluten Challenge and Drug Treatment},
  journal = {International Journal of Molecular Sciences},
  year = {2023},
  doi = {10.3390/ijms241310815}
}
Kostenlos starten →